Maharashtra Herald

Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies – Pfizer, Takeda, Amgen, Abbvie, Roche, AstraZeneca, GSK, BMS, Janssen, Merck

 Breaking News
  • No posts were found

Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies – Pfizer, Takeda, Amgen, Abbvie, Roche, AstraZeneca, GSK, BMS, Janssen, Merck

August 03
11:10 2022
Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Pfizer, Takeda, Amgen, Abbvie, Roche, AstraZeneca, GSK, BMS, Janssen, Merck
Delveinsight Business Research LLP
As per DelveInsight, the Multiple Myeloma Therapeutics market is expected to grow in the upcoming years owing to the rise in incident cases, high adoption of newer therapies, rich emerging pipeline, and expected increase in investment in the R&D activities.

Some factors such as toxicities, the burden of long-term therapy, differences in clinical care, and practice patterns between treatment centres, as well as access to and cost of therapy in real-world settings, will play a role in the observed gap between trial-based and real-world outcomes.

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Myeloma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Multiple Myeloma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Multiple Myeloma Market

Multiple Myeloma: An Overview

Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.

Approximately 95% of cases are diagnosed at a distant stage or metastatic stage, and the 5-year relative survival rate for this stage is around 53%. Most researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.

Multiple Myeloma Market Key Facts

  • The United States, in 2020, accounted for 32,270+ cases which is expected to increase in the coming years.

  • Among the EU-5 countries, the highest number of cases of Multiple myeloma was in Germany, i.e. 7,600+ cases in the year 2020.

  • According to DelveInsight’s analysis, males are more affected in the case of Multiple Myeloma (MM) than females.

Multiple Myeloma Market

The Multiple Myeloma market size is expected to increase during the forecast period owing to the increasing incidence of Multiple Myeloma, label expansion of current therapies, and rising awareness of marketed therapies.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Multiple Myeloma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Multiple Myeloma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Multiple Myeloma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Multiple Myeloma Epidemiology Segmentation

  • Total Incident Cases of Multiple Myeloma

  • Gender-specific cases of Multiple Myeloma

  • Total Symptomatic Cases of Multiple Myeloma 

  • Diagnosed cases of Multiple Myeloma by Age Distribution

  • Cases of Multiple Myeloma by Treatment Line

Multiple Myeloma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/multiple-myeloma-market

Multiple Myeloma Therapeutics Analysis

The Multiple Myeloma market dynamics are anticipated to change in the coming years owing to the launch of novel drugs and the rise in healthcare spending worldwide. 

Some of the Key companies in the Multiple Myeloma therapeutics domain include:

  • Pfizer

  • Takeda

  • Amgen

  • Abbvie

  • AbbVie

  • Roche

  • AstraZeneca

  • GlaxoSmithKline

  • Bristol-Myers Squibb

  • Janssen Research & Development

  • Merck Sharp & Dohme Corp.

And many others.

Multiple Myeloma Therapies covered in the report include:

  • Descartes-11

  • Venetoclax

  • REGN5458

  • Iberdomide

  • Imfinzi (Durvalumab;MEDI4736)

  • Braftovi (encorafenib)

  • Motixafortide (BL-8040)

  • Felzartamab (MOR202)

  • Chidamide (Epidaza)

  • Keytruda (Pembrolizumab)

  • Cetrelimab (JNJ-63723283)

  • Ciltacabtagene Autoleucel (cilta-cel/JNJ-68284528/LCAR-B38M)

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/multiple-myeloma-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Multiple Myeloma Competitive Intelligence Analysis

4. Multiple Myeloma Market Overview at a Glance

5. Multiple Myeloma Disease Background and Overview

6. Multiple Myeloma Patient Journey

7. Multiple Myeloma Epidemiology and Patient Population

8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Myeloma Unmet Needs

10. Key Endpoints of Multiple Myeloma Treatment

11. Multiple Myeloma Marketed Products

12. Multiple Myeloma Emerging Therapies

13. Multiple Myeloma Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Myeloma Market Outlook (7 major markets)

16. Multiple Myeloma Access and Reimbursement Overview

17. KOL Views on the Multiple Myeloma Market.

18. Multiple Myeloma Market Drivers

19. Multiple Myeloma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/multiple-myeloma-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Otoscope Market
“Otoscope Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Otoscope. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Otoscope market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/